Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 10, 2005 - Issue 2
Submit an article Journal homepage
90
Views
5
CrossRef citations to date
0
Altmetric
Review

Emerging drugs for bacterial urinary tract infections

Florian ME WagenlehnerHospital St. Elisabeth Urologic Clinic, St. Elisabeth Street. 23, D-94315, Straubing GermanyTel: + 49 9421 710 6702; Fax: + 49 9421 710 1717;E-mail: [email protected]
,
Wolfgang WeidnerUniversity Giessen Department of Urology, Rudolf-Buchheim-Street. 7, D-35385, Giessen Germany
&
Kurt G NaberHospital St. Elisabeth Urologic Clinic, St. Elisabeth Street. 23, D-94315, Straubing GermanyTel: + 49 9421 710 6702; Fax: + 49 9421 710 1717;E-mail: [email protected]
Pages 275-298 | Published online: 10 May 2005

Bibliography

  • WARREN JW, ABRUTYN E, HEBEL JR, JOHNSON JR, SCHAEFFER AJ, STAMM WE: Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin. Infect. Dis. (1999) 29:745–758.
  • ••Important meta-analysis about the antibiotic treatment of uncomplicated cystitis and uncomplicated pyelonephritis.
  • FOXMAN B: Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am. J. Med. (2002) 113(Suppl. 1A):55–513.
  • MAZZULLI T: Resistance trends in urinary tract pathogens and impact on management. j UroL (2002) 168:1720–1722.
  • GALES AC, JONES RN, GORDON KA et al.: Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY antimicrobial surveillance program (1998). J. Antimicrob. Chemother. (2000) 45:295–303.
  • RODEN H, GASTMEIER P, DASCHNER FD, SCHUMACHER M: Nosocomial and community-acquired infections in Germany. Summary of the results of the first national prevalence study (NIDEP). Infection (1997) 25:199–202.
  • •National prevalence study in Germany about nosocomial infections in different departments throughout the hospital.
  • MAKI DG, TAMBYAH PA: Engineering out the risk of infection with urinary catheters. Emerg. Infect. Dis. (2001) 7:1–6.
  • ••Concise overview on catheter-associatedUTI. Substantial data on epidemiology and treatment strategies.
  • PATTON JP, NASH DB, ABRUTYN E: Urinary tract infection: economic considerations. Med. Clin. North Am. (1991) 75:495–513.
  • GUPTA K, HOOTON TM, STAMM WE: Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann. Intern. Med. (2001) 135:41–50.
  • BARNETT BJ, STEPHENS DS: Urinary tract infection: an overview. Am. J. Med. Sci. (1997) 314:245–249.
  • HOOTON TM: The current management strategies for community-acquired urinary tract infection. Infect. Dis. Clin. North Am. (2003) 17:303–332.
  • FIT-IN SD: Clinical practice. Acute uncomplicated urinary tract infection in women. N EngL J. Med. (2003) 49:259–266.
  • KAHLMETER G: An international survey of the antimicrobial susceptibility of pathogens from uncompicated urinary tract infections: the ECO-SENS project. J. Antimicrob. Chemother. (2003) 51:69–76.
  • TALAN DA, STAMM WE, HOOTON TM et al.: Comparison of ciprofloxacin (7 days) and trimethoprim- sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial. JAMA (2000) 283:1583–1590.
  • JONES RN, KUGLER KC, PFALLER MA, WINOKUR PL: Characteristics of pathogens causing urinary tract infections in hospitals in North America: results from the SENTRY Antimicrobial Surveillance Program, 1997. Diagn. Microbiol. Infect. Dis. (1999) 35:55–63.
  • GORDON KA, JONES RN: Susceptibilitypatterns of orally administered antimicrobials among urinary tract infection pathogens from hospitalized patients in North America: comparison report to Europe and Latin America. Results from the SENTRY Antimicrobial Surveillance Program (2000). Diagn. Microbiol. Infect. Dis. (2003) 45:295–301.
  • MATHAI D, JONES RN, PFALLER MA: Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: a report from the SENTRY Antimicrobial Surveillance Program (North America). Diagn. Microbiol. Infect. Dis. (2001) 40:129–136
  • BOUZA E, SAN JUAN R, MUNOZ P, VOSS A, KLUYTMANS J; Co-operative group of the European Study Group on Nosocomial Infections (ESGNI): a European perspective on nosocomial urinary tract infections I. Report on the microbiology workload, etiology and antimicrobial susceptibility (ESGNI-003 study). Clin. Microbiol. Infect. (2001) 7:523–531.
  • WAGENLEHNER FM, NIEMETZ A. DALHOFF A, NABER KG: Spectrum and antibiotic resistance of uropathogens from hospitalized patients with urinary tract infections: 1994-2000. Int. J. Antimicrob. Agents (2002) 19:557–564.
  • ABRAHAM EP, CHAIN E: An enzyme from bacteria able to destroy penicillin. Nature (1940) 146:837.
  • KARLOWSKY JA, KELLY LJ, THORNSBERRY G et al.: Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Tracking resistance in the United States today. The Surveillance Network. Int. J. Antimicrob. Agents (2002) 19:21–31.
  • KARLOWSKY JA, KELLY LJ, THORNSBERRY C, JONES ME, SAHM DF: Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob. Agents Chemother. (2002) 46:2540–2545.
  • MORRISSEY I, FARRELL DJ, ROBBINS M, WERLING H-0, FELINGHAM D: Surveillance of the antibiotic susceptibility of urinary tract infection (UTI) pathogens in Europe from outpatients (OUT) and inpatients (IN) during 1999/2000. Clin. Microbiol Infect. (2003) 9\(Suppl. 1):Abstract.
  • LUNA CM, VUJACICH P, NIEDERMAN MS et al.: Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest (1997) 111:676–685.
  • MONTRAVERS P, GAUZIT R, MULLER C, MARMUSE JP, FICHELLE A. DESMONTS JM: Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin. Infect. Dis. (1996) 23: 486–494.
  • ELHANAN G, SARHAT M, RAZ R: Empiric antibiotic treatment and the missuse of culture results and antibiotic sensitivities in patients with community-acquired bacteraemia due to urinary tract infection. J. Infect. (1997) 35:283–288.
  • •Clinical study highlighting the importance of empiric antibiotic treatment.
  • MILLER LG, TANG AW: Treatment ofuncomplicated urinary tract infections in an era of increasing antimicrobial resistance. Mayo Clin. Proc. (2004) 79:1048–1053.
  • SCHAEFFER AJ: The expanding role offluoroquinolones. Dis. Mon. (2003) 49:129–147.
  • HISANAGA TL, DECORBY MR, LAINGK NM et al.: Antibiotic resistance in outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Abstracts of the 4Ist Annual Meeting of the Infectious Diseases Society of America. San Diego, CA, USA (2003).
  • SCHITO GC: Why fosfomycin trometamol as first line therapy for uncomplicated UTI? Int. J Antimicrob. Agents. (2003) 22:79–83.
  • UNGHERI D, ALBINI E, BELLUCO G: In-vitro susceptibility of quinolone-resistant clinical isolates of Escherichia coli to fosfomycin trometamol. J. Chemother. (2002) 14:237–240.
  • LECOMTE F, ALLAERT FA: Le traitement monodose de la cystite par fosfomycin trometamol. Analyse de 15 essais comparatifs portant sur 2048 malades. Midecine et Maladies infectieuses (1996) 26:338–343.
  • GRANINGER W: Pivmecillinam-therapy of choice for lower urinary tract infection. Int. J. Antimicrob. Agents. (2003) 22:73–78.
  • NICOLLE LA: Pivmecillinam in the treatment of urinary tract infections. Antimicrob. Chemother. (2000) 46:35–39.
  • STEIN GE: Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection. Clin. Ther. (1999) 21:1864–1872.
  • HOOTON TM: The current management strategies for community-acquired urinary tract infection. Infect. Dis. Clin. North Am. (2003) 17:303–332.
  • TALAN DA, KLIMBERG IW, NICOLLE LE, SONG J, KOWALSKY SF, CHURCH DA: Once daily, extended release ciprofloxacin for complicated urinary tract infections and acute uncomplicated pyelonephritis. j Urol (2004) 171:734–739.
  • NABER KG, BARTNICKI A. BISCHOFF W et al.: Gatifloxacin 200 mg or 400 mg once daily is as effective as ciprofloxacin 500 mg twice daily for the treatment of patients with acute pyelonephritis or complicated urinary tract infections. Int. J. Antimicrob. Agents. (2004) 23(Suppl. 1):41–53.
  • NABER KG, SCHOENWALD S, HAUKE W: Cefpodoxime proxetil in patients with acute uncomplicated pyelonephritis. International, prospective, randomized comparative study versus ciprofloxacin in general practice. (Article in German). Chemotherapie Journal (2001) 10:29–34.
  • STAMM WE, MCKEVITT M, COUNTS GW: Acute renal infection in women:treatment with trimethoprim-sulfamethoxazole or ampicillin for two or six weeks. Ann. Intern. Med. (1987) 106:341–345.
  • RICHARD GA, KLIMBERG IN, FOWLER CL, CALLERY-D'AMICO S, KIM SS: Levofloxacin versus ciprofloxacin versus lomefloxacin in acute pyelonephritis. Urology (1998) 52:51–55.
  • VOGEL F, NABER KG, WACHA H et al.: Parenterale Antibiotika bei Erwachsenen. Chemotherapie Journal (1999) 8:2–49.
  • NABER KG, FONFSTÜCK R, GATERMANN S, HOYME U: Infektionen der Nieren und des Urogenitaltraktes. Chemotherapie Journal (2004) 13:78–84.
  • BAUER HW, BLEBMANN GS, PITROW DB, RAHLFS VW: Prevention of recurrent urinary tract infections with immunoactive E. coli fractions. Eur. Obstet. Gyn. (1999) 86:33.
  • BAUER HW, RAHLFS VW, LAUENER PA, BLEBMANN GS: Prevention of recurrent urinary tract infections with immunoactive E. coli fractions: a meta-analysis of five placebo-controlled double-blind studies. Int. J. Antimicrob. Agents (2002) 19:451–456.
  • RIEDASCH G, MOHRING K: Immunisierungstherapie rezidivierender Harnwegsinfekte der Frau. Therapiewoche (1986) 6:896–900.
  • CARLSSON S, GOVONI M, WIKLUND NP, WEITZBERG E, LUNDBERG JO: In vitro evaluation of a new treatment for urinary tract infections caused by nitrate-reducing bacteria. Antimicrob. Agents Chemother. (2003) 47:3713–3718.
  • MULVEY MA, SCHILLING JD, MARTINEZ JJ, HULTGREN SJ: Bad bugs and beleagured bladders: interplay between uropathogenic Escherichia coli and innate host defenses. Proc. Natl. Acad. Sci. USA (2000) 97:8829–8835.
  • •Important new pathogenic concept in bladder infection.
  • MARTINEZ JJ, MULVEY MA, SCHILLING JD, PINKNER JS HULTGREN SJ: Type 1 pilus-mediated bacterial invasion of bladder epithelial cells. Eur. Mol. Biol. Organ (2000) 12:2803–2812.
  • SAMUELSSON P, HANG L, WULLT B, IRJALA H, SVANBORG C: Toll-like receptor 4 expression and cytokine responses in the human urinary tract mucosa. Infect. Immun. (2004) 72:3179–3186.
  • •Important new pathogenic concept in UTI.
  • SCHILLING JD, MARTIN SM, HUNSTAD DA et al.: CD14- and Toll-like receptor-dependent activation of bladder epithelial cells by lipopolysaccharide and Type 1 piliated Escherichia coli. Infect. Immun. (2003) 71:1470–1480.
  • SVANBORG C: Bacterial induction of inflammation in the urinary tract [abstract1355]. In: Programme of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC, USA (1999):770.
  • GEERLINGS SE, STOLK RP, CAMPS MJ et al.: Asymptomatic bacteriuria may be considered a complication in women with diabetes. Diabetes Care (2000) 23:744–749.
  • GEERLINGS SE, BROUWER EC, VAN KESSEL CP et al.: Cytokine secretion is impaired in women with diabetes mellitus [abstract1609]. In: Programme of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC, USA (1999):388.
  • HVIDBERG H, STRUVE C, KROGFELT KA et al.: Development of a long-term ascending urinary tract infection mouse model for antibiotic treatment studies. Antimicrob. Agents Chemother. (2000) 44:156–163.
  • NICKEL C, OLSON ME, COSTERTON JW: Rat model of experimental bacterial prostatitis. Infection (1991) 19:126–130.
  • COSTERTON JW: Introduction to biofilm. Int. j Antimicrob. Agents (1999) 11:217–221.
  • REID G: Biofilms in infectious disease andon medical devices. Int. j Antimicrob. Agents (2003) 22:223–226.
  • TENKE P: Biofilm infection in UTI. In: Hot topics in urinary tract infections. UTI Symposium, Budapest, Hungary (2003).
  • GOTO T, NAKAME Y, NISHIDA M, OHI Y: Bacterial biofilms and catheters in experimental urinary tract infection. Int. J. Antimicrob. Agents (2003) 22:227–231.
  • MARCHESE A, BOZZOLASCO M, GUALCO L, DEBBIA EA, SCHITO GC, SCHITO AM: Effect of fosfomycin alone and in combination with N-acetylcysteine on E. coli biofilms. Int. j Antimicrob. Agents (2003) 22:95–100.
  • DRLICA K, ZHAO X: DNA gyrase, topoisomerase, and the 4-quinolones. Microbio. Molecular Bio. Reviews (1997) 61:377–392.
  • LEHN N: Mechanismen der Resistenzentwicklung gegen Antibiotika, Epidemiologie. In: Die Infektiologie. Adam D, Doerr HW, Link H, Lode H (Eds). Springer-Verlag, Berlin, Heidelberg, Germany (2004):82–98.
  • BURCHALL JJ, ELWELL LP, FLING ME: Molecular mechanisms of resistance to trimethoprim. Rev. Infect. Dis. (1982) 4:246–254.
  • THEN RL: Mechanisms of resistance to trimethoprim, the sulfonamides, and trimethoprim-sulfamethoxazole. Rev. Infect. Dis. (1982) 4:261–269.
  • PARK H, BRADRICK TD, HOWELL EE: A glutamine 67 -> histidine mutation in homotetrameric R67 dihydrofolate reductase results in four mutations per single active site pore and causes substantial substrate and cofactor inhibition. Protein Eng. (1997) 10: 1415–1424.
  • SHINABARGER D: Mechanism of action of the oxazolidinone antibacterial agents. Expert Opin. Invest. Drugs (1999) 8:1195–1202.
  • PECHERE JC, MICHEA-HAMZHEPOUR M, KOHLER T: Antibiotic efflux, a mechanism of multiple resistance in Pseudomonas aeruginosa. Bull. Acad. Natl. Med. (1998) 182:599–612.
  • PIDDOCK LJ: Mechanisms of fluoroquinolone resistance: an update 1994–1998. Drugs (1999) 58(Suppl. 2):11–18.
  • TANAKA M, ONODERA Y, UCHIDA Y, SATO K, HAYAKAWA I: Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus auretts. Antimicrobial Agents Chemother. (1997) 41: 2362–2366.
  • LINDE HJ, SCHMIDT M, FUCHS E, REISCHL U, NILLER HH, LEHN N: In vitro activities of six quinolones and mechanisms of resistance in Staphylococcus aureus and coagulase-negative staphylococci. Antimicrobial Agents Chemother. (2001) 45:1553–1557.
  • NAVIA MM, RUIZ J, RIBERA A, DE ANTA MT, VILA J: Analysis of the mechanisms of quinolone resistance in clinical isolates of Citrobacter Antimicrob. Chemother. (1999) 44:743–748.
  • FONTANA R, LIGOZZI M, PITTALUGA F, SATTA G: Intrinsic penicillin resistance in enterococci. Microb. Drug Resist. (1996) 2:209–213.
  • MARSHALL CG, BROADHEAD G, LESKIW BK, WRIGHT GD: D-Ala-D-Ala ligases from glycopeptide antibiotic-producing organisms are highly homologous to the enterococcal vancomycin-resistance ligases VanA and VanB. Proc. Natl. Acad. Sci. USA (1997) 94:6480–6483.
  • LIVERMORE DM: Antibiotic resistance instaphylococci. Int. J. Antimicrob. Agents (2000) 16(Suppl. 1):3–10.
  • STAPLETON P, WU PJ, KING A, SHANNON K, FRENCH G, PHILLIPS I: Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Eschericia coli. Antimicrob. Agents Chemother. (1995) 39:2478–2483.
  • CHAVES J, LADONA MG, SEGURA C, COIRA A, REIG R, AMPURDANSE C: SHV-1 beta-lactamase is mainly a chromosomally encoded species-specific enzyme in Klebsiella pneumoniae. Antimicrob. Agents Chemother. (2001) 45:2856–2861.
  • YANG YJ, LIVERMORE DM, WILLIAMS RJ: Chromosomal beta-lactamase expression and antibiotic resistance in Enterobacter cloacae. J. Med. MicrobioL (1988) 25:227–233.
  • BONNET R, DE CHAMPS C, SIROT D, CHANAL C, LABIA R, SIROT J: Diversity of TEM mutants in Proteus mirabilis. Antimicrob. Agents Chemother. (1999) 43:2671–2677.
  • PATTERSON JE. Extended-spectrum beta-lactamases. Semin. Respir. Infect. (2000) 15:299–307.
  • JONES RN: Resistance patterns among nosocomial pathogens: trends over the past few years. Chest (2001) 119 (Suppl. 2):397–404.
  • CULEBRAS E, MARTINEZ JL: Aminoglycoside resistance mediated by the bifunctional enzyme 6'-N-aminoglycoside acetyltransferase-2'-0-aminoglycoside phosphotransferase. Front Biosci. (1999) 4:D1–D8.
  • AMINOGLYCOSIDE RESISTANCE STUDY GROUPS: The most frequently occurring amoinoglycoside resistance mechanisms-combined results of surveys in eight regions of the world. J. Chemother. (1995) 7(Suppl. 2):17–30.
  • SNYDMAN DR, JACOBUS NV, MCDERMOTT LA et al.: Comparative in vitro activities of daptomycin and vancomycin against resistant Gram-positive pathogens. Antimicrob. Agents Chemother. (2000) 44:3447–3450.
  • LAGANAS V ALDER J, SILVERMAN JA: In vitro bactericidal activities of daptomycin against Staphylococcus aureus and Enterococcus faecahs are not mediated by inhibition of lipoteichoic acid biosynthesis. Antimicrob. Agents Chemother. (2003) 47:2682–2684.
  • FUCHS PC, BARRY AL, BROWN SD: In vitro bactericidal activity of daptomycin against staphylococci. J. Antimicrob. Chemother. (2002) 49:467–470.
  • LOUIE A, KAW P, LIU W et ell.: Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob. Agents Chemother. (2001) 45:845–851.
  • WOODWORTH JR, NYHART EH Jr, BRIER GL et al.: Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob. Agents Chemother. (1992) 36:318–325.
  • DE BRUIN MF, TALLY FP: Efficacy and safety of daptomycin for the treatment of bacteremia and serious infections due to Gram-positive bacteria. 4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections. Atlanta, GA, USA (2000).
  • HENRY DC Jr, BETTIS RB, RIFFER E et al.: Comparison of once-daily extended-release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women. Clin. Ther. (2002) 24:2088–2104.
  • THEIL FP, FREDE M, STASS H: Population pharmacokinetic characterization of the new ciprofloxacin MR formulation with ciprofloxacin IR [abstract]. Clin. MicrobioL Infect. (2003) 9\(Suppl. 1).
  • TALAN DA, NABER KG, PALOU J, ELKHARRAT D: Extended-release ciprofloxacin (Cipro XR) for treatment of urinary tract infections. Int. J. Antimicrob. Agents (2004) 23:54–66.
  • UEHLING DT, HOPKINS WJ, ELKAHWAJI JE, SCHMIDT DM, LEVERSON GE: Phase II clinical trial of a vaginal mucosal vaccine for uirnary tract infections. J. Urol (2003) 170:867–869.
  • LI X, MOBLEY HL: Vaccines for Proteus mirabilis in urinary tract infection. Int. J. Antimicrob. Agents (2002) 19:461–465.
  • DRLICA K: A strategy for fighting antibiotic resistance. ASM News (2001) 67:27–33.
  • CHENG Q, NELSON D, ZHU S, FISCHETTI VA: Removal of group B streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme. Antimicrob. Agents Chemother. (2005) 49:111–117.
  • YOONG P, SCHUCH R, NELSON D, FISCHETTI VA: Identification of a broadly active phage lytic enzyme with lethal activity against antibiotic-resistant Enterococcus faecahs and Enterococcus faecium. J Bacteriol (2004) 186:4808–4812.
  • NEU HC: The crisis in antibiotic resistance. Science (1992) 257: 1064–1073.

Websites

  • http://www.iddb3.com/ Investigational Drugs database, © 1997–2005 Thomson Scientific Ltd.
  • http://www.uroweb.org/ index.php?structure_id=516 Pan-european-prevalence study on nosocomially acquired UTI (NAUTI) (2003).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.